- Full Year 2023 Transgene SA Earnings Call TranscriptMar 27, 2024€1.08 (-0.55%)Earnings
- Half Year 2023 Transgene SA Earnings Call TranscriptSep 20, 2023€1.81 (+1.80%)Earnings
- Transgene SA Conference Call TranscriptMay 05, 2023
- Full Year 2022 Transgene SA Earnings Call TranscriptMar 16, 2023€1.91 (-1.55%)Earnings
- Transgene SA Interim Analysis of TG4001 Phase II Trial Call TranscriptNov 02, 2022
- Transgene SA R&D Day TranscriptSep 27, 2022
- Q2 2022 Transgene SA Earnings Call TranscriptSep 07, 2022€2.06 (+0.49%)Earnings
- Q4 2021 Transgene SA Earnings Call TranscriptMar 16, 2022€2.22 (+6.47%)Earnings
- Transgene SA Corporate Call TranscriptDec 15, 2021
- Transgene SA TG4050 Phase I Studies Results Webcast TranscriptNov 23, 2021
- Q2 2021 Transgene SA Earnings Call TranscriptSep 22, 2021€2.41 (+1.26%)Earnings
- Transgene SA Presents Results From the Phase 1b/2 trial of TG4001 in Combination with Avelumab Conference Call TranscriptNov 12, 2020
- Transgene SA Results from Clinical Study of TG4001 in Combination with Avelumab Conference Call TranscriptJul 22, 2020
- Q4 2019 Transgene SA Earnings Call TranscriptMar 11, 2020€1.23 (+6.59%)Earnings
Transgene SA TG4050 Phase I Studies Results Webcast Transcript
Welcome to the Transgene Conference Call. Please note this conference is being recorded. (Operator Instructions). I will now hand over to your host, Lucie Larguier, Head of Investor Relations, to begin today's conference. Thank you.
Thank you. Hello, everyone. I'm Lucie Larguier, Director of Investor Relations at Transgene. So today, we're going to present the first positive results of the clinical trials evaluating TG4050, our individualized cancer immunotherapy.
With me today are Hedi Ben Brahim, CEO of Transgene; Eric Quemeneur, Chief Scientific Officer; Maud Brandely, Chief Medical Officer; and Kaidre Bendjama, Director Next-Generation Vaccine.
We are honored to be joined by Prof. Christian Ottensmeier, MD, PhD, who is the Professor of Immuno-Oncology at the University of Liverpool and the Global Coordinator of the Head and Neck Trials, currently evaluating TG4050.
I remind you that today's discussion contains forward-looking statements, which are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)